Protagonist Therapeutics Files 8-K: Material Agreement

TL;DR

Protagonist Therapeutics signed a big deal on Nov 13th. Details in the 8-K.

AI Summary

On November 13, 2024, Protagonist Therapeutics, Inc. entered into a Material Definitive Agreement. The filing also notes other events and includes financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.

Why It Matters

This 8-K filing indicates a significant new agreement for Protagonist Therapeutics, which could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood.

Key Players & Entities

• Protagonist Therapeutics, Inc. (company) — Registrant
• November 13, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 7707 Gateway Blvd., Suite 140 (address) — Business and mailing address

FAQ

Key Financial Figures

• $0.00001 — h registered Common Stock, par value $0.00001 PTGX The Nasdaq Stock Market LLC
• $50 m — cation meeting its primary endpoint) by $50 million, from $115 million to $165 millio
• $115 million — primary endpoint) by $50 million, from $115 million to $165 million; (b) eliminates the $3
• $165 million — t) by $50 million, from $115 million to $165 million; (b) eliminates the $35 million milest
• $35 million — on to $165 million; (b) eliminates the $35 million milestone payment in Section 7.3.1(E) (
• $15 million — ny indication); and (c) eliminates the $15 million milestone payment in Section 7.3.1(L) (

Filing Documents

• tm2428765d1_8k.htm (8-K) — 29KB
• tm2428765d1_ex99-1.htm (EX-99.1) — 23KB
• tm2428765d1_ex99-1img001.jpg (GRAPHIC) — 4KB
• 0001104659-24-120165.txt ( ) — 236KB
• ptgx-20241113.xsd (EX-101.SCH) — 3KB
• ptgx-20241113_lab.xml (EX-101.LAB) — 33KB
• ptgx-20241113_pre.xml (EX-101.PRE) — 22KB
• tm2428765d1_8k_htm.xml (XML) — 4KB

01. Entry into a Material

Item 1.01. Entry into a Material Definitive Agreement On November 13, 2024, Protagonist Therapeutics, Inc. (the " Company ") and Janssen Biotech, Inc., a Pennsylvania corporation (" Janssen ") entered into an amendment (the " Amendment ") to their amended and restated License and Collaboration Agreement dated July 27, 2021 (the " Collaboration Agreement "). The Amendment: (a) increases the milestone payment set forth in Section 7.3.1(D) (for a Phase 3 clinical trial for any Licensed Product for any indication meeting its primary endpoint) by $50 million, from $115 million to $165 million; (b) eliminates the $35 million milestone payment in Section 7.3.1(E) (for acceptance of filing of an NDA by the FDA for use of Licensed Product in any indication); and (c) eliminates the $15 million milestone payment in Section 7.3.1(L) (for dosing of the 3 rd patient in the first Phase 3 clinical trial of a Licensed Product for a second indication). The $165 million milestone now payable pursuant to Section 7.3.1(D) of the Collaboration Agreement has been earned as a result of the Phase 3 clinical trial results described in the press release attached hereto as Exhibit 99.1 . Accordingly, the Amendment has the effect of accelerating the $35 million and $15 million milestone payments set forth in Sections 7.3.1(E) and 7.3.1(L) of the Collaboration Agreement.

01. Other Events

Item 8.01. Other Events On November 18, 2024, the Company issued a press release related to Phase 3 clinical study results for icotrokinra (JNJ-2113, formerly PN-235), which is a Licensed Product under the Collaboration Agreement. The press release is attached hereto as Exhibit 99.1 .

01 Financial Statements

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release, dated November 18, 2024, titled "Protagonist announces positive topline results from Phase 3 ICONIC studies of icotrokinra (JNJ-2113) in plaque psoriasis, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). The information in Item 8.01 of this report, including the exhibit hereto, shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 8.01 of this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Protagonist Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagonist Therapeutics, Inc. Dated: November 18, 2024 By: /s/ Asif Ali Asif Ali Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR